1-(3-chlorophenyl)-4-[1-(3-((3-(2-hydroxy-1-ethoxy)phenyl)oxy)-4-cyanobenzyl)-5-imidazolylmethyl]-2-piperazinone | 360561-53-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(3-chlorophenyl)-4-[1-(3-((3-(2-hydroxy-1-ethoxy)phenyl)oxy)-4-cyanobenzyl)-5-imidazolylmethyl]-2-piperazinone
• 英文别名: 4-((5-((4-(3-chlorophenyl)-3-oxopiperazin-1-yl)methyl)-1H-imidazol-1-yl)methyl)-2-phenoxybenzonitrile；Prenyl-IN-1；4-[[5-[[4-(3-chlorophenyl)-3-oxopiperazin-1-yl]methyl]imidazol-1-yl]methyl]-2-phenoxybenzonitrile
• CAS: 360561-53-1
• 化学式: C₂₈H₂₄ClN₅O₂
• 分子量: 497.984
• InChiKey: JAUARQFUHQYXHN-UHFFFAOYSA-N

物化性质

• 沸点：
  756.2±60.0 °C(Predicted)
• 密度：
  1.28±0.1 g/cm3(Predicted)
• 溶解度：
  溶于二甲基亚砜

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  36
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  74.4
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-氟-4-甲基苯腈 在 lithium hydroxide 、 N-溴代丁二酰亚胺(NBS) 、 4 A molecular sieve 、 三氧化硫吡啶 、 三乙酰氧基硼氢化钠 、 caesium carbonate 、 三乙胺 、 过氧化苯甲酰 作用下， 以 四氢呋喃 、 四氯化碳 、 二甲基亚砜 、 乙酸乙酯 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 1-(3-chlorophenyl)-4-[1-(3-((3-(2-hydroxy-1-ethoxy)phenyl)oxy)-4-cyanobenzyl)-5-imidazolylmethyl]-2-piperazinone
  参考文献：
  名称：

  Aryloxy substituted N-arylpiperazinones as dual inhibitors of farnesyltransferase and geranylgeranyltransferase-I

  摘要：

  A series of aryloxy substituted piperazinones with dual farnesyltransferase/geranylgeranyltransferase-I inhibitory activity was prepared. These compounds were found to have potent inhibitory activity in vitro and are promising agents for the inhibition of Ki-Ras signaling. (C) 2001 Published by Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00240-2

文献信息

• Compounds which inhibits protein prenylation ( e.g. geranylgeranyltransferase or farnesyltransferase inhibitors) for treating Parkinson's disease
  申请人：Exonhit Therapeutics SA

  公开号：EP1656931A1

  公开（公告）日：2006-05-17

  The invention relates to compounds and their uses, particularly in the pharmaceutical industry. The invention more specifically relates to new uses of compounds that inhibit the prenylation of proteins, in particular the geranylgeranyl and/or farnesyl modifications of proteins, for treating neurodegeneration involving oxidative stress and, more particularly, Parkinson's disease. The invention also relates to corresponding methods of treatment, and can be used in human subjects for preventive or curative treatment, either alone or in combination with other active agents or treatments.

  本发明涉及化合物及其用途，尤其是在制药业中的用途。本发明更具体地涉及抑制蛋白质的前酰化，特别是抑制蛋白质的香叶基和/或法呢基修饰的化合物的新用途，用于治疗涉及氧化应激的神经变性，特别是帕金森病。本发明还涉及相应的治疗方法，可用于人体的预防或治疗，可单独使用，也可与其他活性剂或治疗方法联合使用。
• COMPOUNDS WHICH INHIBITS PROTEIN PRENYLATION E.G. GERANYLGERANYLTRANSFERASE OR FARNESYLTRANSFERASE INHIBITORS FOR TREATING PARKINSON'S DISEASE
  申请人：Exonhit Therapeutics SA

  公开号：EP1811984A1

  公开（公告）日：2007-08-01
• Compounds Which Inhibits Protein Prenylation E.G. Geranylgeransferse or Farnesyltransferase Inhibitors for Treating Parkinson's Disease
  申请人：Schweighoffer Fabien

  公开号：US20080153758A1

  公开（公告）日：2008-06-26

  The invention relates to compounds and their uses, particularly in the pharmaceutical industry. The invention more specifically relates to new uses of compounds that inhibit the prenylation of proteins, in particular the geranylgeranyl and/or farnesyl modifications of proteins, for treating neurodegeneration involving oxidative stress and, more particularly, Parkinson's disease. The invention also relates to corresponding methods of treatment, and can be used in human subjects for preventive or curative treatment, either alone is or in combination with other active agents or treatments.
• [EN] COMPOUNDS WHICH INHIBITS PROTEIN PRENYLATION E.G. GERANYLGERANYLTRANSFERASE OR FARNESYLTRANSFERASE INHIBITORS FOR TREATING PARKINSON'S DISEASE<br/>[FR] COMPOSES INHIBANT LA PRENYLATION DE PROTEINES, NOTAMMENT DES INHIBITEURS DE LA GERANYLGERANYLTRANSFERASE OU DE LA FARNESYLTRANSFERASE, UTILISES DANS LE TRAITEMENT DE LA MALADIE DE PARKINSON
  申请人：EXONHIT THERAPEUTICS SA

  公开号：WO2006051423A1

  公开（公告）日：2006-05-18

  [EN] The invention relates to compounds and their uses, particularly in the pharmaceutical industry. The invention more specifically relates to new uses of compounds that inhibit the prenylation of proteins, in particular the geranylgeranyl and/or farnesyl modifications of proteins, for treating neurodegeneration involving oxidative stress and, more particularly, Parkinson's disease. The invention also relates to corresponding methods of treatment, and can be used in human subjects for preventive or curative treatment, either alone is or in combination with other active agents or treatments.
  [FR] L'invention concerne des composés et leurs utilisations, en particulier dans le secteur pharmaceutique. L'invention concerne plus particulièrement de nouvelles utilisations de composés inhibant la prénylation de protéines, en particulier les modifications géranylgéranyle et/ou farnésyle de protéines, dans le traitement de la neurodégénérescence impliquant le stress oxydatif et, plus particulièrement, dans la traitement de la maladie de Parkinson. L'invention concerne également des méthodes de traitement correspondantes pouvant être mises en oeuvre pour le traitement préventif ou thérapeutique de patients humains, seules ou en association avec d'autres principes actifs ou traitements.
• [EN] TREATMENT OF VIRAL INFECTION WITH PRENYLTRANSFERASE INHIBITORS<br/>[FR] TRAITEMENT D'UNE INFECTION VIRALE AVEC DES INHIBITEURS DE PRÉNYLTRANSFÉRASE
  申请人：EIGER BIOPHARMACEUTICALS INC

  公开号：WO2011088126A2

  公开（公告）日：2011-07-21

  Inhibitors of prenylation such as farnesyl transferase inhibitors can be used to treat HDV infection.